

# ISO/TS 21405:2026-03 (E)

## Health informatics - Identification of medicinal products - Methodology and framework for the development and representation of IDMP ontology

---

| <b>Contents</b>   |   | <b>Page</b> |
|---|---|-------------|
| Foreword .....  |   | iv          |
| Introduction .....  |   | v           |
| <b>1</b>  | <b>Scope .....</b>  | <b>1</b>    |
| <b>2</b>  | <b>Normative references .....</b>   | <b>1</b>    |
| <b>3</b>  | <b>Terms and definitions .....</b>  | <b>1</b>    |
| <b>4</b>  | <b>Benefits of an ontological approach for IDMP .....</b>   | <b>4</b>    |
| 4.1   | General .....   | 4           |
| 4.2   | Recommended methodology for collaborative IDMP ontology development - Ontology governance in a collaborative ontology development framework ..... | 4           |
| 4.3   | Governance structures in ontology development and maintenance in alignment with the ISO standards on IDMP .....                                   | 5           |
| <b>5</b>  | <b>Use cases for an IDMP ontology .....</b>   | <b>6</b>    |
| 5.1   | Practical applications of IDMP ontology in regulatory frameworks .....  | 6           |
| 5.2   | Identifying substances, pharmaceutical and medicinal products unambiguously .....   | 6           |
| 5.2.1   | Use case 1 (UC1): Ensuring unambiguous identification of substances .....   | 6           |
| 5.2.2   | Area of focus .....   | 7           |
| 5.2.3   | UC1 description .....   | 7           |
| 5.2.4   | Stakeholders, actors, interfaces .....  | 8           |
| 5.2.5   | UC1 usage scenarios .....   | 8           |
| 5.3   | Enabling interoperability between regulatory, manufacturing and healthcare domains .....  | 14          |
| 5.3.1   | Use case 2 (UC2): overview .....  | 14          |
| 5.3.2   | Scope of UC2 .....  | 14          |
| 5.3.3   | Stakeholders and actors .....   | 15          |
| 5.3.4   | UC2 description .....   | 15          |
| 5.3.5   | Usage scenarios .....   | 18          |
| 5.3.6   | Competency questions .....  | 19          |
| 5.4   | Jurisdiction-agnostic medicinal products .....  | 23          |
| 5.4.1   | Use case overview .....   | 23          |
| 5.4.2   | Competency question (CQ) .....  | 24          |
| 5.5   | Ensuring interoperability between regulatory, clinical development and healthcare domains .....   | 24          |
| 5.5.1   | Use case overview .....   | 24          |
| 5.5.2   | Linking therapeutic indication(s) to their medicinal products and associated active substances: competency question .....                         | 25          |
| 5.6   | Ensuring global interoperability for the detection of supply chain and drug shortages .....   | 25          |
| Annex A (informative) Examples of regional implementation ..... |   | 26          |
| Bibliography .....  |   | 30          |